2Lee K W,Park J W,Joh J W,et al.Can we expand the Milan criteria for hepatocellular carcinoma in living donor liver transplantation[J]? Transplant Proc,2004,36:2289-2290.
3Gondolesi G E,Roayaie S,Munoz L,et al.Adult living donor liver transplantation for patients with hepatocellular carcinoma:extending UNOS priority criteria[J].Ann Surg,2004,239:142-149.
4Jemal A,Murray T,Ward E,et al.Cancer statistics[J].CA Cancer J Clin,2005,55:10-30.
5Tang Z Y,Ye S L,Liu Y K,et al.A decade's studies on metastasis of hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2004,130:187.
6Mazzaferro V,Regalia E,Doci R,et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J].N Engl J Med,1996,334:693-699.
7Leung J Y,Zhu A X,Gordon F D,et al.Liver transplantation outcomes for early-stage hepatocellular carcinoma:results of a multicenter study[J].Liver Transpl,2004,10:1343-1354.
8Margarit C,Charco R,Hidalgo E,et al.Liver transplantation for malignant diseases:selection and pattern of recurrence[J].World J Surg,2002,26:257-263.
9Khakhar A,Solano E,Stell D,et al.Survival after liver transplantation for hepatocellular carcinoma[J].Transplant Proc,2003,35:2438-2441.
10Wiesner R H.MELD/PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure,primary nonfunction,hepatic artery thrombosis,and acute Wilson's disease[J].Liver Transpl,2004,10:S17-22.
1Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis [J].Biomarkers, 2004, 9(1) :1-31.
2Wishart DS. Metabolomics: the principles and potential applications to transplantation [ J ]. Am J Transplant, 2005, 5 ( 12 ) :2814-2820.
3Melendez HV, Rela M, Setchell KDR, et al. Bile acids analysis: a tool to assess graft function in human liver ramsplantation [J]. Transpl Int, 2004, 17(6) :286-292.
4Melendez HV, Ahmadi D, Parkes HG, et al. Proton nuclear magnetic resonance analysis of hepatic bile from donors and recipients in human liver .transplantation[J].Transplantation, 2001,72(5) :855-860.
5Singh HK, Yachha SK, Saxena R, et al. A new dimension of i H NMR spectroscopy in assessment of liver graft dysfunction [J]. NMR Biomed, 2003, 16(4) :185-188.
6Yang J, Zhao X, Liu X, et al. High performance liquid chromatography-mass spectrometry for metabonomics: potential biomarkers for acute deterioration of liver function in chronic hepatitis B [ J ]. J Proteome Res, 2006, 5 ( 3 ) : 554-561.
7Yang J, Xu G, Zheng Y, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases [J].J Chromatogr B, 2004, 813(1-2) :59-65.
8Yang J, Xu G, Hong Q, et al. Discrimination of type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles [J]. J Chromatogr B, 2004, 813(1-2) :53-58.
9Katz-BruU R, Seger D, Rivenson-Segal D, et al. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis [J]. Cancer Res, 2002, 62(7):1966-1970.
10Morvan D, Demidem A, Papon J, et al. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscaopy of intact tumor samples [J]. Cancer Res , 2.002, 62(6) :1890-1897.
